Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind and placebo-controlled phase III study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S

Next Previous
X
Search
Trial Profile

A randomized, double-blind and placebo-controlled phase III study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Basal cell cancer; Carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Biofrontera AG

    • Most Recent Events

    • 24 May 2022 According to a Biofrontera media release, to date, 75% of the planned 186 patients have been enrolled in the study
    • 01 Feb 2022 According to a Biofrontera media release, to date, 70% of the planned 186 patients have been enrolled in the study. Patient recruitment for this study has been ongoing since 2018 with completion of patient recruitment anticipated by the end of 2022
    • 01 Feb 2022 Status changed from planning to recruiting, according to a Biofrontera media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top